SAFC is spending $10.1 million to expand facilities in Ireland and Switzerland. The company reports plans to increase cGMP commercial-scale API manufacturing capacity at its Arklow, Ireland, plant and to expand production and storage at the Buchs, Switzerland, buildings.
These developments come shortly after SAFC’s decision last month to enhance the high-potency intermediates production and solid-form research at its Madison, WI, facility. In April the company also reported the completion of two new protein purification and extraction API facilities at its St. Louis, MO, manufacturing campus.
Scheduled for the first quarter of 2008, the $4.7 million Arklow investment will increase production capacity and capability. The pilot plant will be upgraded and vessels will be added to increase chemistry capacity for API products. SAFC expects to complete other enhancements later this year that will increase utility capacity and the site’s environmental performance.
SAFC will provide another $5.4 million for a 17,200 sq. ft. expansion to its existing cGMP production plant at Buchs. Production capacity will go up 25% through improved materials flow and separation and increased materials storage, according to the company. The two-level storage building is expected to become fully operational in spring 2008 and will reportedly provide logistical infrastructure to support future expansion.